[go: up one dir, main page]

DE69636764D1 - Zusammensetzungen zur behandlung von ischamischem gewebe - Google Patents

Zusammensetzungen zur behandlung von ischamischem gewebe

Info

Publication number
DE69636764D1
DE69636764D1 DE69636764T DE69636764T DE69636764D1 DE 69636764 D1 DE69636764 D1 DE 69636764D1 DE 69636764 T DE69636764 T DE 69636764T DE 69636764 T DE69636764 T DE 69636764T DE 69636764 D1 DE69636764 D1 DE 69636764D1
Authority
DE
Germany
Prior art keywords
tissue
ischemia
ischemic
ischamic
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69636764T
Other languages
English (en)
Other versions
DE69636764T2 (de
Inventor
M Isner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Elizabeths Medical Center of Boston Inc
Original Assignee
St Elizabeths Medical Center of Boston Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24178424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69636764(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by St Elizabeths Medical Center of Boston Inc filed Critical St Elizabeths Medical Center of Boston Inc
Application granted granted Critical
Publication of DE69636764D1 publication Critical patent/DE69636764D1/de
Publication of DE69636764T2 publication Critical patent/DE69636764T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Laser Surgery Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Steroid Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DE69636764T 1995-10-20 1996-10-18 Zusammensetzungen zur behandlung von ischamischem gewebe Expired - Lifetime DE69636764T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US545998 1983-10-27
US08/545,998 US6121246A (en) 1995-10-20 1995-10-20 Method for treating ischemic tissue
PCT/US1996/016723 WO1997014307A1 (en) 1995-10-20 1996-10-18 Method for treating ischemic tissue

Publications (2)

Publication Number Publication Date
DE69636764D1 true DE69636764D1 (de) 2007-01-25
DE69636764T2 DE69636764T2 (de) 2007-10-31

Family

ID=24178424

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69636764T Expired - Lifetime DE69636764T2 (de) 1995-10-20 1996-10-18 Zusammensetzungen zur behandlung von ischamischem gewebe
DE69637800T Expired - Lifetime DE69637800D1 (de) 1995-10-20 1996-10-18 Verbindungen zur Behandlung der ischaemischen Gewebe

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69637800T Expired - Lifetime DE69637800D1 (de) 1995-10-20 1996-10-18 Verbindungen zur Behandlung der ischaemischen Gewebe

Country Status (8)

Country Link
US (1) US6121246A (de)
EP (2) EP1625858B1 (de)
JP (3) JPH11514366A (de)
AT (2) ATE347910T1 (de)
AU (1) AU725290B2 (de)
CA (1) CA2235372C (de)
DE (2) DE69636764T2 (de)
WO (1) WO1997014307A1 (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238673B2 (en) 1989-03-31 2007-07-03 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US6706694B1 (en) 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
WO1995003843A1 (en) * 1993-07-30 1995-02-09 The Regents Of The University Of California Endocardial infusion catheter
DK0751992T3 (da) 1994-03-08 2006-03-06 Human Genome Sciences Inc Karendotelvækstfaktor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US20030148968A1 (en) * 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
ATE292476T1 (de) * 1995-08-29 2005-04-15 Anges Mg Inc Ein medikament,das hgf gen enthält
ES2247621T3 (es) 1996-02-15 2006-03-01 Biosense Webster, Inc. Sonda de excavacion.
US20080305999A1 (en) * 1996-11-01 2008-12-11 John Francis Martin Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia
ATE279518T1 (de) * 1997-01-29 2004-10-15 Cornell Res Foundation Inc An verschiedenen orten verabreichung von adenoviren-vektor zur induzierung von angiogenese
DE69830320T2 (de) * 1997-03-07 2006-02-02 The Wistar Institute Of Anatomy And Biology Verwendung von Adenoviralen Vektoren, die PDGF oder VEGF exprimieren, ZUR HEILUNG VON GEWEBSDEFEKTEN UND ZUR INDUZIERUNG DER HYPERVASKULITÄT IN SÄUGERGEWEBEN
WO1999017798A1 (en) * 1997-10-02 1999-04-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
CA2311643C (en) * 1997-12-04 2009-04-07 Genzyme Corporation Compositions and methods for inducing gene expression
DE69838526T2 (de) 1998-02-05 2008-07-03 Biosense Webster, Inc., Diamond Bar Gerät zum Freisetzen eines Medikaments im Herzen
US6676937B1 (en) * 1998-03-09 2004-01-13 Caritas St. Elizabeth's Medical Center Of Boston Inc. Compositions and methods for modulating vascularization
US20040228834A1 (en) * 1998-03-09 2004-11-18 Jeffrey Isner Compositions and methods for modulating vascularization
US6958147B1 (en) * 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
ES2296420T3 (es) 1998-11-13 2008-04-16 Daikin Industries, Ltd. Composicion azeotropica consistente en 1,1,1,3,3-pentafluoropropano y 1,1,1,-trifluoro-3-cloro-2-propeno, su procedimiento de separacion y purificacion, y procedimiento de produccion de 1,1,1,3,3-pentafluoropropano y de 1,1,1,-trifluoro-3-cloro-2-propeno.
DE19857609A1 (de) * 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
EP1016726A1 (de) * 1998-12-30 2000-07-05 Introgene B.V. Gentherapie zur Förderung der Angiogenesis
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
US6440945B1 (en) * 1999-05-27 2002-08-27 Instituto Dermopatico Dell'immacolata Method of inducing angiogenesis in nonis chemic skeletal muscle
US20030236214A1 (en) * 1999-06-09 2003-12-25 Wolff Jon A. Charge reversal of polyion complexes and treatment of peripheral occlusive disease
EP1067190A1 (de) * 1999-07-09 2001-01-10 Introgene B.V. Gentherapie zur Erhöhung und/oder Induktion der Angiogenese
US6936594B1 (en) * 1999-09-21 2005-08-30 Ryuichi Morishita Gene therapy for cerebrovascular disorders
EP1136083B1 (de) 1999-10-08 2008-05-14 AnGes MG, Inc. Hgf zur gentherapie der karidomyopathie
ATE409494T1 (de) * 1999-10-29 2008-10-15 Anges Mg Inc Gentherapie für diabetische ischämie
US6748258B1 (en) * 1999-11-05 2004-06-08 Scimed Life Systems, Inc. Method and devices for heart treatment
US6329348B1 (en) 1999-11-08 2001-12-11 Cornell Research Foundation, Inc. Method of inducing angiogenesis
US20040072785A1 (en) * 1999-11-23 2004-04-15 Wolff Jon A. Intravascular delivery of non-viral nucleic acid
US7727971B2 (en) 2000-02-04 2010-06-01 Life Sciences Research Partners Vzw Use of placental growth factor for treating ischemic muscle disease
US7105168B1 (en) 2002-06-04 2006-09-12 D. Collen Research Foundation Vzw Method of improving ischemic muscle function by administering placental growth factor
AU4643501A (en) * 2000-02-04 2001-08-14 Flanders Interuniversity Institute For Biotechnology (Vib) Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke
US6930089B2 (en) 2000-02-04 2005-08-16 D. Collen Research Foundation Vzw Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic disease or stroke
CA2413768A1 (en) * 2000-06-27 2002-01-03 Anges Mg, Inc. Pharmaceutical compositions for angiogenic therapy
MXPA02003434A (es) * 2000-08-04 2002-09-02 Human Genome Sciences Inc Factor de crecimiento endotelial vascular 2.
CN1526014A (zh) * 2000-10-06 2004-09-01 ��ʽ���������о��� 用于将外源基因导入骨骼肌的副粘病毒载体
US20040009940A1 (en) * 2000-10-20 2004-01-15 Coleman Michael E. Gene delivery formulations and methods for treatment of ischemic conditions
EP1330252A4 (de) * 2000-11-01 2007-12-26 Ludwig Inst Cancer Res In-vivo-stimulierung der angiogenen aktivität
JP2002142770A (ja) * 2000-11-08 2002-05-21 Dnavec Research Inc 循環系への遺伝子送達用パラミクソウイルスベクター
JP4212357B2 (ja) * 2000-11-27 2009-01-21 株式会社ディナベック研究所 血管新生遺伝子をコードするパラミクソウイルスベクターおよびその利用
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20020168739A1 (en) * 2001-03-09 2002-11-14 Wu Kenneth K. Vectors, compositions and methods for treating a vascular disorder
US20020131959A1 (en) * 2001-03-14 2002-09-19 Ivo Buschmann Means and methods for the modulation of arteriogenesis
WO2002081634A2 (en) * 2001-04-05 2002-10-17 The Johns Hopkins University Imaging nucleic acid delivery
MXPA03009408A (es) 2001-04-13 2004-01-29 Human Genome Sciences Inc Factor de crecimiento endotelial vascular 2.
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
CA2444624A1 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7182944B2 (en) * 2001-04-25 2007-02-27 The United States Of America As Represented By The Department Of Health And Human Services Methods of increasing distribution of nucleic acids
DE10122855A1 (de) * 2001-05-11 2002-11-14 Max Planck Gesellschaft Mittel zur Verbesserung der Gewebepenetration
EP1581241A4 (de) * 2001-06-20 2005-11-09 Ludwig Inst Cancer Res Stimulation von vaskularisierung mit vegf-b
US7217570B2 (en) * 2001-08-23 2007-05-15 The Wistar Institute Of Anatomy And Biology Organotypic intestinal culture and methods of use thereof
US20040031067A1 (en) * 2001-10-11 2004-02-12 Meenhard Herlyn Regulation of human skin healing
KR100562824B1 (ko) * 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
PL195457B1 (pl) * 2002-08-05 2007-09-28 Zaklady Farm Polpharma Sa Kaseta ekspresyjna, dwucistronowy wektor plazmidowy, środek farmaceutyczny oraz ich zastosowanie
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
WO2008121719A1 (en) * 2007-03-30 2008-10-09 The Cleveland Clinic Foundation Method of treating ischemic disorders
RU2232022C1 (ru) * 2002-12-02 2004-07-10 Государственное образовательное учреждение высшего профессионального образования башкирский государственный медицинский университет Способ профилактики и лечения ишемической болезни сердца
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US6817068B2 (en) * 2003-01-02 2004-11-16 The Burton Corporation Adjustable length strap assembly
WO2004098534A2 (en) * 2003-02-24 2004-11-18 Therion Biologics Corporation Methods for delivering angiogenic modulators using pox viruses
EP1603945A2 (de) * 2003-03-12 2005-12-14 Advisys, Inc. Plasmid-vermittelte ergänzung von insulinähnlichem wachstumsfaktor (igf-i) für therapeutische anwendungen
MXPA05010345A (es) * 2003-03-27 2006-03-08 Johnson & Johnson Uso de la eritropoyetina en la recuperacion del accidente cerebrovascular.
EA009390B1 (ru) * 2003-06-05 2007-12-28 Сентельон Плазмида, кодирующая фактор роста фибробластов, для лечения ангиогенных дефектов, ассоциированных с гиперхолестеринемией или диабетом
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
EP2081956B1 (de) 2006-11-13 2013-03-20 Charité - Universitätsmedizin Berlin Zellkulturverfahren und behandlungsverfahren mit einer vepo-protein-variante
EP2036571A1 (de) 2007-09-13 2009-03-18 Sygnis Bioscience GmbH & Co. KG Verwendung von G-CSF für die Behandlung von Schlaganfall
AU2008338525B2 (en) 2007-12-14 2015-04-02 Juventas Therapeutics, Inc. Compositions and methods of promoting wound healing
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
EP2281040B1 (de) * 2008-04-09 2015-11-25 Viromed Co., Ltd. Lyophilisierte dna-formulierungen zur verbesserten expression von plasmid-dna
WO2011026041A2 (en) 2009-08-28 2011-03-03 The Cleveland Clinic Foundation Sdf-1 delivery for treating ischemic tissue
WO2011054829A1 (en) * 2009-11-03 2011-05-12 Roche Diagnostics Gmbh NT-pro ANP AND SFlt-1 FOR THE DIFFERENTIATION BETWEEN CIRCULATORY AND ISCHEMIC EVENTS
RU2426174C1 (ru) * 2010-03-29 2011-08-10 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ фармакологической коррекции ишемии конечности, в том числе при l-name индуцированном дефиците оксида азота
US10149864B2 (en) 2013-03-13 2018-12-11 The University Of Queensland Method of isolating cells for therapy and prophylaxis
JP6240337B2 (ja) 2013-10-22 2017-11-29 バイロメッド カンパニー リミテッド 肝細胞増殖因子の２つ以上のアイソフォームを利用した筋萎縮性側索硬化症の予防又は治療用組成物
BR112021000722A2 (pt) 2018-07-19 2021-05-04 Helixmith Co., Ltd. composições farmacêuticas liofilizadas para terapia gênica de dna nu

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
DE69034078T2 (de) * 1989-03-21 2004-04-01 Vical, Inc., San Diego Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
CA2112375A1 (en) * 1991-06-28 1993-01-07 Elizabeth G. Nabel Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5661133B1 (en) * 1991-11-12 1999-06-01 Univ Michigan Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein
ATE307212T1 (de) * 1992-11-18 2005-11-15 Arch Dev Corp Adenovirus-gelenkter gen-transfer zum herz-und glatten vaskulären muskel
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US6086866A (en) * 1993-04-29 2000-07-11 Kouri; Roger Khalil Use of platelet-derived growth factor to improve collateral circulation
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy

Also Published As

Publication number Publication date
EP1625858A1 (de) 2006-02-15
DE69636764T2 (de) 2007-10-31
ATE419014T1 (de) 2009-01-15
AU7454896A (en) 1997-05-07
US6121246A (en) 2000-09-19
JP2008024718A (ja) 2008-02-07
EP1625858B1 (de) 2008-12-31
CA2235372A1 (en) 1997-04-24
CA2235372C (en) 2009-01-27
DE69637800D1 (de) 2009-02-12
JPH11514366A (ja) 1999-12-07
JP2011219502A (ja) 2011-11-04
WO1997014307A1 (en) 1997-04-24
EP0883343A1 (de) 1998-12-16
EP0883343B1 (de) 2006-12-13
AU725290B2 (en) 2000-10-12
EP0883343A4 (de) 2002-04-10
ATE347910T1 (de) 2007-01-15

Similar Documents

Publication Publication Date Title
DE69636764D1 (de) Zusammensetzungen zur behandlung von ischamischem gewebe
DE69434431D1 (de) Methoden zur behandlung von muskelerkrankungen und muskelstörungen
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
EA200300845A1 (ru) Модифицированные антитела и способы применения
EA199801044A1 (ru) Модуляторы регенерации тканей
ATE145564T1 (de) Anordnung zur bestrahlung von laserstrahlen
BR9915573A (pt) Processo de preparação de uma composição protéica e uma fórmula infantil contendo a mesma
ATE330631T1 (de) Antikörperfragmente zur lokalen behandlung von augenerkrankungen
ATE177954T1 (de) Verfahren zur behandlung von knochengeweben und implantierbare biomaterialien dafür
ATE284959T1 (de) Unterbrechung der bindung der proteine mdm2 und p53 und entsprechende therapeutische anwendung
FI900808A0 (fi) Humant mannos bindande protein.
DE69032200D1 (de) Verfahren zur Behandlung von Schnittblumen
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
DE69835680D1 (de) Therapeutische verwendung von smr1 protein und seinen aktiven derivaten
ATE484294T1 (de) Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
EP1499190A4 (de) Verfahren zur behandlung von lebererkrankungen und leberschäden mit wachstumshormon und foxm1b
EA200001124A1 (ru) Способ генной терапии
DE69129267D1 (de) Methode zur behandlung intestinaler krankheiten
DE69932922D1 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen
DE59508509D1 (de) Dna-expressionsvektoren zur verwendung in der gentherapeutischen behandlung von gefässerkrankungen
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
ATE275580T1 (de) Verfahren zur induktion der herstellung von wachstumsfaktoren
EP1143996A4 (de) Methode zur behandlung von chronischen herzerkrankungen
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8330 Complete renunciation